Iantrek Publishes Clinical Results of Uveoscleral Outflow Technology for Open-Angle Glaucoma
Iantrek announced the publication of clinical results highlighting the efficacy of Iantrek’s uveoscleral outflow technology for the treatment of glaucoma.
The results, published in the Journal of Clinical Medicine, were first presented at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Boston. The data was collected as part of the CREST registry, the largest real-world evidence study to date on uveoscleral outflow enhancement in patients with open-angle glaucoma.
The procedure, which uses Iantrek’s proprietary cyclodialysis system and its allogeneic bio-interventional technology, demonstrated robust clinical outcomes with a low incidence of adverse events, according to a company news release. This minimally invasive surgical approach is designed to enhance aqueous drainage through the uveoscleral outflow pathway—one of the most promising and underutilized therapeutic strategies in glaucoma treatment.
“Enhancing aqueous drainage through the uveoscleral outflow pathway represents a breakthrough in glaucoma surgery,” Dr. Leon W. Herndon, one of the lead study authors, said in a company news release. “Iantrek’s technology addresses a significant unmet need in glaucoma treatment. This bio-interventional approach is not only biocompatible but also free from implantable hardware, offering surgeons an elegant solution for unlocking a major aqueous drainage pathway.”
Iantrek’s proprietary technology uses natural, homologous tissue, making it a bioconforming option that aligns with the body’s natural anatomy, potentially reducing postoperative complications. The company is poised to redefine how glaucoma is managed surgically, providing a breakthrough option for ophthalmologists and patients alike.
The uveoscleral outflow pathway has been a longstanding target in glaucoma pharmacotherapy, but no interventional technologies currently available in the US market focus specifically on this pathway. With Iantrek’s technique, the company aims to set a new standard for the surgical treatment of glaucoma, offering patients a safer and more effective alternative.